ADMA Biologics Inc (ADMA)
6.55
+0.11
(+1.71%)
USD |
NASDAQ |
Apr 26, 16:00
6.54
-0.01
(-0.15%)
After-Hours: 20:00
ADMA Biologics Research and Development Expense (Quarterly): 0.4455M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.4455M |
| September 30, 2023 | 0.5959M |
| June 30, 2023 | 1.403M |
| March 31, 2023 | 0.8554M |
| December 31, 2022 | 1.075M |
| September 30, 2022 | 1.042M |
| June 30, 2022 | 0.8734M |
| March 31, 2022 | 0.6241M |
| December 31, 2021 | 0.7289M |
| September 30, 2021 | 0.7706M |
| June 30, 2021 | 1.159M |
| March 31, 2021 | 0.9876M |
| December 31, 2020 | 1.014M |
| September 30, 2020 | 1.708M |
| June 30, 2020 | 1.656M |
| March 31, 2020 | 1.529M |
| December 31, 2019 | 0.4648M |
| September 30, 2019 | 0.4914M |
| June 30, 2019 | 0.517M |
| March 31, 2019 | 0.8706M |
| December 31, 2018 | 0.9173M |
| September 30, 2018 | 1.003M |
| June 30, 2018 | 1.040M |
| March 31, 2018 | 0.9656M |
| Date | Value |
|---|---|
| December 31, 2017 | 1.205M |
| September 30, 2017 | 1.814M |
| June 30, 2017 | 1.358M |
| March 31, 2017 | 1.193M |
| December 31, 2016 | 0.5834M |
| September 30, 2016 | 1.677M |
| June 30, 2016 | 3.400M |
| March 31, 2016 | 2.028M |
| December 31, 2015 | 1.997M |
| September 30, 2015 | 2.112M |
| June 30, 2015 | 1.506M |
| March 31, 2015 | 1.402M |
| December 31, 2014 | 1.920M |
| September 30, 2014 | 1.483M |
| June 30, 2014 | 1.784M |
| March 31, 2014 | 4.330M |
| December 31, 2013 | 2.956M |
| September 30, 2013 | 1.409M |
| June 30, 2013 | 3.470M |
| March 31, 2013 | 1.468M |
| December 31, 2012 | 1.268M |
| September 30, 2012 | 1.941M |
| June 30, 2012 | 0.1787M |
| March 31, 2012 | 0.0818M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.4455M
Minimum
Dec 2023
1.708M
Maximum
Sep 2020
0.9442M
Average
0.8734M
Median
Jun 2022
Research and Development Expense (Quarterly) Benchmarks
| Vanda Pharmaceuticals Inc | 24.34M |
| ANI Pharmaceuticals Inc | 9.867M |
| Ligand Pharmaceuticals Inc | 5.488M |
| Puma Biotechnology Inc | 12.87M |
| Bristol-Myers Squibb Co | 2.695B |